Literature DB >> 24384815

Induction of tolerance through mixed chimerism.

David H Sachs1, Tatsuo Kawai, Megan Sykes.   

Abstract

"Mixed chimerism" refers to a state in which the lymphohematopoietic system of the recipient of allogeneic hematopoietic stem cells comprises a mixture of host and donor cells. This state is usually attained through either bone marrow or mobilized peripheral blood stem cell transplantation. Although numerous treatment regimens have led to transplantation tolerance in mice, the induction of mixed chimerism is currently the only treatment modality that has been successfully extended to large animals and to the clinic. Here we describe and compare the use of mixed chimerism to establish transplantation tolerance in mice, pigs, monkeys, and in the clinic. We also attempt to correlate the mechanisms involved in achieving tolerance with the nature of the tolerance that has resulted in each case.

Entities:  

Mesh:

Year:  2014        PMID: 24384815      PMCID: PMC3869282          DOI: 10.1101/cshperspect.a015529

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  131 in total

1.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.

Authors:  Carrie L Lucas; Creg J Workman; Semir Beyaz; Samuel LoCascio; Guiling Zhao; Dario A A Vignali; Megan Sykes
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys.

Authors:  Ognjenka Nadazdin; Svjetlan Boskovic; Toru Murakami; D H O'Connor; Roger W Wiseman; J A Karl; J J Tuscher; D H Sachs; J C Madsen; Georges Tocco; Tatsuo Kawai; A B Cosimi; Gilles Benichou
Journal:  Am J Transplant       Date:  2010-05-14       Impact factor: 8.086

Review 3.  Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Authors:  Samuel Strober; Thomas R Spitzer; Robert Lowsky; Megan Sykes
Journal:  Semin Immunol       Date:  2011-06-25       Impact factor: 11.130

Review 4.  Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism.

Authors:  Tatsuo Kawai; A Benedict Cosimi; David H Sachs
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

5.  Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation.

Authors:  G Andreola; M Chittenden; J Shaffer; A B Cosimi; T Kawai; P Cotter; S A Locascio; T Morokata; B R Dey; N T Tolkoff-Rubin; F Preffer; T Bonnefoix; K Kattleman; T R Spitzer; D H Sachs; M Sykes
Journal:  Am J Transplant       Date:  2011-06       Impact factor: 8.086

6.  An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching.

Authors:  C P Larsen; A Page; K H Linzie; M Russell; T Deane; L Stempora; E Strobert; M C T Penedo; T Ward; R Wiseman; D O'Connor; W Miller; S Sen; K Singh; L S Kean
Journal:  Am J Transplant       Date:  2010-09-17       Impact factor: 8.086

7.  Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance.

Authors:  Samuel A LoCascio; Tatsuaki Morokata; Meredith Chittenden; Frederic I Preffer; David M Dombkowski; Giovanna Andreola; Kerry Crisalli; Tatsuo Kawai; Susan L Saidman; Thomas R Spitzer; Nina Tolkoff-Rubin; A Benedict Cosimi; David H Sachs; Megan Sykes
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

8.  Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease.

Authors:  Thomas R Spitzer; Megan Sykes; Nina Tolkoff-Rubin; Tatsuo Kawai; Steven L McAfee; Bimalangshu R Dey; Karen Ballen; Francis Delmonico; Susan Saidman; David H Sachs; A Benedict Cosimi
Journal:  Transplantation       Date:  2011-03-27       Impact factor: 4.939

9.  Recipient dendritic cells, but not B cells, are required antigen-presenting cells for peripheral alloreactive CD8+ T-cell tolerance.

Authors:  J L Mollov; C L Lucas; F Haspot; J Kurtz C Gaspar; A Guzman; M Sykes
Journal:  Am J Transplant       Date:  2010-02-01       Impact factor: 8.086

10.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

View more
  53 in total

1.  Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned.

Authors:  Thomas R Spitzer; Nina Tolkoff-Rubin; A Benedict Cosimi; Steven McAfee; Bimalangshu R Dey; Yi-Bin Chen; Francis Delmonico; Megan Sykes; David H Sachs; Tatsuo Kawai
Journal:  Transplantation       Date:  2019-11       Impact factor: 4.939

Review 2.  Tolerance--is it worth it?

Authors:  Erik B Finger; Terry B Strom; Arthur J Matas
Journal:  Cold Spring Harb Perspect Med       Date:  2014-02-01       Impact factor: 6.915

Review 3.  Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Authors:  Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh
Journal:  Semin Hematol       Date:  2018-04-25       Impact factor: 3.851

Review 4.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

5.  CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection.

Authors:  Vyacheslav Palchevskiy; Ying Ying Xue; Rita Kern; Stephen S Weigt; Aric L Gregson; Sophie X Song; Michael C Fishbein; Cory M Hogaboam; David M Sayah; Joseph P Lynch; Michael P Keane; David G Brooks; John A Belperio
Journal:  JCI Insight       Date:  2019-05-14

6.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 7.  Transplant trials with Tregs: perils and promises.

Authors:  Qizhi Tang; Flavio Vincenti
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

8.  Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.

Authors:  Benson M George; Kevin S Kao; Hye-Sook Kwon; Brenda J Velasco; Jessica Poyser; Angela Chen; Alan C Le; Akanksha Chhabra; Cassandra E Burnett; Devon Cajuste; Malachia Hoover; Kyle M Loh; Judith A Shizuru; Irving L Weissman
Journal:  Cell Stem Cell       Date:  2019-06-13       Impact factor: 24.633

9.  Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization.

Authors:  Nina Pilat; Benedikt Mahr; Lukas Unger; Karin Hock; Christoph Schwarz; Andreas M Farkas; Ulrike Baranyi; Fritz Wrba; Thomas Wekerle
Journal:  JCI Insight       Date:  2016-05-19

10.  Overcoming immunological barriers in regenerative medicine.

Authors:  Johannes L Zakrzewski; Marcel R M van den Brink; Jeffrey A Hubbell
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.